Navigation Links
Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity
Date:1/4/2012

MORRISTOWN, N.J., Jan. 4, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it recently received approval from the US Food & Drug Administration to market Methylphenidate Hydrochloride Extended-Release Capsules (LA) CII, USP, 20mg, 30mg, and 40mg.  Actavis has first-to-file exclusivity on the 20mg, 30mg, and 40mg strengths. Distribution of the product has commenced. 

Methylphenidate Hydrochloride Extended-Release Capsules 20mg, 30mg and 40mg, the generic equivalent of Ritalin LA® 20mg, 30mg, and 40mg, had US sales of approximately $80.7 million for the 12 months ending September 30, 2011, according to IMS Health.   

Commenting on the new approval, Doug Boothe, CEO of Actavis in the US, said:

"The approval and launch of Methylphenidate Hydrochloride Extended-Release Capsules (LA) offers a significant value to our customers and patients.  This approval, along with the first-to-file exclusivity, also underscores Actavis' emphasis and commitment to bringing complex controlled-release products to the marketplace."

Please see prescribing information at www.actavis.us/methylphenidate.

About Actavis:

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

Ritalin LA® is a registered trademark of a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion
2. Actavis to Launch Novel Pain Medication in the US
3. QRxPharma Announces Strategic Partnership with Actavis
4. Actavis Launches Generic KADIAN® Capsules in the U.S.
5. Actavis Plans Latin America Expansion
6. Actavis Launches Generic Keppra XR® Tablets in the U.S.
7. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
8. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
9. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
10. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
11. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Pharmaceuticals Inc., the creator of the drug Truveta for the ... an IPO. The United States spends ... a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... figure is the fact that Americans spent $42 billion on anxiety medications ...
(Date:8/10/2017)... Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired the ... Lakewood, Colorado . The reputable clinic will continue ... PT, DPT with his staff of four clinicians. Lipkin received ... and brings over 10 years of experience with a strong ... Belmar PT marks the 10th PRN clinic in and around the ...
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... 2017 , ... Parker at Stonegate, an assisted living residence ... caregivers, volunteers, thought leaders, researchers, educators and partners leading the way in services ... refresh the carpeting with the goal of maintaining the same precise colors and ...
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of ... Congo (DRC) thanks to an ambitious venture that conjoined the passions of an NBA ... support of the Liberty community. These shoes will save lives from the rampant infections ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... edition of “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... ... 2017 , ... Hernandez Insurance Agencies, a northern Virginia firm ... DC region, is inaugurating a “New Leash On Life” charity initiative in conjunction ... to be companions for veterans in need. , The Semper K9 organization works ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an ... is campaigning in support of Campagna Academy in a charity drive to provide for ... Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization that has offered critical ...
Breaking Medicine News(10 mins):